Actively Recruiting
Observational Study of PulseSelect PFA System for Atrial Fibrillation Treatment and Follow-up
Led by Medtronic Cardiac Ablation Solutions · Updated on 2026-10-28
580
Participants Needed
23
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a global, multi-center observational trial to study patients with recurrent symptomatic paroxysmal or persistent atrial fibrillation AF. The trial evaluates the PulseSelect PFA System, a market-approved device used for pulmonary vein isolation, to better understand its safety and effectiveness over a 36-month period. This study follows patients who have not responded well to at least one Class I or III antiarrhythmic drug. Participants will undergo an ablation procedure using the PulseSelect PFA System according to standard hospital care. The study observes two groups based on AF type paroxysmal and persistent. After treatment, patients will be followed with scheduled visits at 3, 6, 12, 24, and 36 months, including 24-hour Holter heart monitoring at the 6, 12, 24, and 36 month visits. During the study, participants will have regular assessments to track heart rhythm and safety outcomes. Researchers will measure freedom from atrial fibrillation at 36 months after ablation and monitor for device- or procedure-related adverse events up to 6 months. The total participant involvement spans three years, providing long-term data on treatment outcomes and safety.
CONDITIONS
Brief Title
PULSED AF Post-Approval Study
Research Team
J
Josman Suri
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here